Literature DB >> 16274796

Clinical prognostic factors in malignant parotid gland tumors.

Roberto A Lima1, Marcos R Tavares, Fernando L Dias, Jacob Kligerman, Marilene F Nascimento, Mauro M Barbosa, Claudio R Cernea, Jose R Soares, Izabella C Santos, Scheylla Salviano.   

Abstract

OBJECTIVE: To analyze the factors in parotid malignant epithelial tumors influencing recurrences and disease-specific survival.
METHODS: We retrospectively reviewed the files of 150 patients treated at our institution, from 1974 to 1998. Twenty-four patients were not treated by surgery and were excluded from this study. The remaining 126 patients were treated with surgery and 74 patients had postoperative radiotherapy. Thirty-three patients were treated with parotidectomy plus neck dissection. Neck lymph node metastasis was found in 22 patients, 5 patients had occult neck metastasis, and 4 periparotid lymph nodes metastasis. The mean age was 49 years old. According to the UICC/1997 TNM Classification, 49 patients were stage I, 27 stage II, 22 stage III, and 28 stage IV. The influence of selected factors on the 10 year disease-specific survival was analyzed using the Kaplan-Meier actuarial method and the log-rank test.
RESULTS: Forty patients had mucoepidermoid carcinoma, 18 patients adenocarcinoma NOS, 18 patients acinic cell carcinoma, 15 patients adenoid cystic carcinoma, 11 patients malignant mixed tumor, 11 patients salivary duct carcinoma, and 13 patients other pathology. Twenty-five patients had recurrences: 17 had local recurrences, 4 patients had neck recurrences, and 4 were loco-regional recurrences. Five factors influenced negatively the prognosis: 1) T stage (p.00001), 2) grade (p.00001), 3) + lymph nodes (p.0007), 4) facial nerve dysfunction (p.0001), and 5) age (p.004). Patients with high-grade tumors and high-stage tumors had the worst prognosis according to the multivariate analysis. The 10-year disease-specific survival was 97% for stage I, 81% for stage II, 56% for stage III, and 20% for stage IV.
CONCLUSION: The grade of the tumor and stage were the most important prognostic factor. EBM RATING: C.

Entities:  

Mesh:

Year:  2005        PMID: 16274796     DOI: 10.1016/j.otohns.2005.08.001

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  39 in total

1.  Management of malignant parotid tumors.

Authors:  Nikolaos Papadogeorgakis; Lampros Goutzanis; Vassilis Petsinis; Constantinos Alexandridis
Journal:  Oral Maxillofac Surg       Date:  2011-01-05

2.  Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy.

Authors:  Trevor M Feinstein; Stephen Y Lai; Diana Lenzner; William Gooding; Robert L Ferris; Jennifer R Grandis; Eugene N Myers; Jonas T Johnson; Dwight E Heron; Athanassios Argiris
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

3.  The author's reply regarding "Clinical Behaviours and Prognoses of High and Low Risk Parotid Malignancies Based on Histology".

Authors:  Lei Tao
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-18       Impact factor: 2.503

4.  Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies.

Authors:  Lorenz Kadletz; Klaus Aumayr; Gregor Heiduschka; Sven Schneider; Elisabeth Enzenhofer; Claudia Lill
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-07-28       Impact factor: 2.503

5.  Reoperation following the use of non-standardized procedures for malignant parotid tumors.

Authors:  Xiangmin Zhang; Xiangfu Zeng; Xiaolin Lan; Jing Huang; Keqing Luo; Keqiang Tian; Xiuhong Wu; Fufu Xiao; Shaojin Li
Journal:  Oncol Lett       Date:  2017-09-21       Impact factor: 2.967

6.  Non-enhanced MRI in combination with color Doppler flow imaging for improving diagnostic accuracy of parotid gland lesions.

Authors:  Wei Zhang; Zhichao Zuo; Ningbin Luo; Lianfeng Liu; Guanqiao Jin; Junjie Liu; Danke Su
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-02-12       Impact factor: 2.503

7.  Oncological outcomes of preoperatively unexpected malignant tumors of the parotid gland.

Authors:  Hanaro Park; Sungjun Han; Sung Joon Park; Young Ho Jung; Soon-Hyun Ahn; Woo-Jin Jeong
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-30       Impact factor: 2.503

8.  [Treatment of salivary gland malignancies].

Authors:  Michael Formanek
Journal:  Wien Med Wochenschr       Date:  2008

9.  Oncolytic vaccinia virus therapy of salivary gland carcinoma.

Authors:  Natalya Chernichenko; Gary Linkov; Pingdong Li; Richard L Bakst; Chun-Hao Chen; Shuangba He; Yong A Yu; Nanhai G Chen; Aladar A Szalay; Yuman Fong; Richard J Wong
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-02       Impact factor: 6.223

Review 10.  An update on grading of salivary gland carcinomas.

Authors:  Raja R Seethala
Journal:  Head Neck Pathol       Date:  2009-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.